Key Highlights

● DSS announced a public offering on September 3 and decided not to proceed on September 4.

● DSS Robotics launched on September 8.

● Zoar Limited filed a Form F-4 on September 16 for Impact Biomedical's proposed combination.

● The auditor's opinion on 2025 results included a Going Concern paragraph.

DSS, Inc. (NYSE American:DSS) has had a busy few weeks of corporate announcements, spanning a new robotics unit, a merger-related filing and a financing plan that was launched and then dropped within days. The diversified Holding Company is a small-cap name, and its recent news flow illustrates both the strategic initiatives management is pursuing and the Capital constraints the company has acknowledged.

Latest Company Context

On September 3, 2026, DSS announced a proposed public offering of common stock with Aegis Capital as sole book-runner under an effective Form S-3 shelf registration. On September 4, it announced a decision not to proceed, citing limited remaining capacity under that shelf. On September 8, it launched DSS Robotics, offering AI-driven automation consulting, integration and robotics-as-a-service to enterprises. On September 16, it announced that Zoar Limited had filed a Form F-4 in connection with Impact Biomedical's proposed Business combination, which remains subject to SEC review and other conditions. The company described the robotics unit as targeting enterprise operations, though no Revenue figures for it were disclosed in the announcement. The Zoar filing follows the earlier spin-out of Impact Biomedical, which the April Shareholder letter described as completed.

Key Business Drivers

Earlier in 2026, DSS reported a going concern paragraph in the auditor's opinion on its 2025 annual report, filed in May, though the financial statements were not amended. In April, interim chief executive Jason Grady wrote to shareholders about cost reductions, growth in printed products and commissions, Debt repayments and the completed spin-out of Impact Biomedical. In February, the company closed a roughly $1.0 million underwritten offering of 900,000 shares at $1.00 per share. In June, it withdrew a Form S-1, saying market conditions and deal terms would not reflect its value, while stating that it remained able to access capital markets. Management also said debt repayments had been made.

The key variables are instead liquidity, the execution of new initiatives such as robotics, and the outcome of the Impact Biomedical transaction.

What Investors Should Watch

Funding is the central theme. Management has said it will keep evaluating financing options, yet the September decision not to proceed with an offering pointed to limited shelf capacity. Any new registration, alternative financing or asset transaction could affect the share count and per-share value, depending on terms.

Second, the Impact Biomedical combination with Zoar Limited depends on SEC review of the Form F-4 and other conditions, so timing is uncertain and the deal may change or Fail to close.

Third, the going concern language will likely stay in focus until the company demonstrates improved Liquidity or profitability. The next Quarterly Report could provide updated figures. Finally, whether DSS Robotics produces identifiable revenue or contracts, rather than only a branding change, may become a point of debate among analysts. Any related-party or affiliated transactions disclosed in filings could also Warrant scrutiny.

New Launches Against Unresolved Financing Questions

DSS combines new business launches with unresolved financing questions. The robotics unit and the Impact Biomedical Merger could represent strategic progress, while the going concern opinion, a small recent raise and a cancelled offering underline the Balance Sheet pressure.